HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

This study is comparing a new targeted drug called HEC73543 against standard salvage chemotherapy in people with relapsed or refractory AML (acute myeloid leukemia) that has a specific mutation called FLT3-ITD. FLT3-ITD is a mutation that makes leukemia grow faster and is linked to poorer outcomes. **You may be eligible if...** - You are 18 or older - You have AML (primary or secondary to MDS) that has relapsed or not responded to first-line treatment - Your AML cells test positive for the FLT3-ITD mutation - You are in good enough health to receive salvage chemotherapy **You may NOT be eligible if...** - You have previously been treated with another FLT3 inhibitor drug - Your AML relapsed after or did not respond to more than one prior treatment line - You have certain serious medical conditions that make the treatment unsafe Talk to your doctor to see if this trial is right for you.